WHAT IS
CIK THERAPY?
A complete introduction to Cytokine-Induced Killer cell therapy โ how it works, what cancers it targets, and why it has become one of the most widely used adoptive immunotherapy approaches in China and across East Asia.
analyticsAt a Glance
- check_circleCIK cells are the patient's own immune cells โ expanded in the lab and re-infused to target tumours
- check_circleWell-established safety profile with lower toxicity than CAR-T โ no cytokine release syndrome risk
- check_circleUsed as monotherapy and in combination with surgery, chemotherapy, and radiotherapy
- check_circleWidely available at major cancer centres in China, with an extensive clinical trial base
What Is CIK Cell Therapy?
Cytokine-Induced Killer (CIK) cell therapy is a form of adoptive cellular immunotherapy. Blood is drawn from the patient, specific immune cell populations are isolated and activated using cytokines in the laboratory, and the expanded cells are then infused back into the patient โ where they seek out and destroy tumour cells.
โCIK therapy arms the patient's own immune system with a reinforced, tumour-targeting force โ manufactured specifically from their own biology.โ
Autologous โ From Your Own Blood
CIK cells are derived entirely from the patient's own peripheral blood mononuclear cells (PBMCs). Because the cells are autologous (self-derived), the risk of graft-versus-host reactions is eliminated and no donor matching is required.
Dual Identity: T Cell + NK Cell
CIK cells are a heterogeneous population that co-express both T-cell markers (CD3) and NK-cell markers (CD56), giving them MHC-unrestricted tumour-killing ability โ meaning they can target cancer cells regardless of HLA type.
How CIK Cells Kill Cancer
CIK cells destroy tumour cells through several mechanisms simultaneously โ making them harder for cancers to evade than single-mechanism therapies.
Direct Cytotoxicity
CIK cells contact tumour cells directly and release perforin and granzyme B โ proteins that puncture the cancer cell membrane and trigger programmed cell death (apoptosis).
Cytokine Secretion
Activated CIK cells release IFN-ฮณ, TNF-ฮฑ, and IL-2 into the tumour microenvironment โ cytokines that inhibit tumour growth and recruit additional immune effectors to the site.
MHC-Unrestricted Targeting
Unlike conventional T cells, CIK cells do not require MHC class I antigen presentation to recognise tumour targets โ allowing them to kill cancer cells that downregulate HLA expression as an immune evasion strategy.
NKG2D Receptor Pathway
CIK cells express NKG2D receptors that bind stress ligands (MICA/MICB) overexpressed on tumour cell surfaces โ providing a second layer of tumour recognition independent of T-cell receptor signalling.
Benefits vs Limitations of CIK Therapy
CIK therapy occupies a distinct clinical niche among adoptive cell therapies โ well-established and broadly applicable, but with different potency and specificity characteristics compared to engineered T-cell approaches.
Benefits
- Favourable safety profileNo cytokine release syndrome (CRS) or ICANS risk โ the severe toxicities associated with CAR-T therapy are not seen with CIK infusions.
- No HLA matching requiredMHC-unrestricted killing means CIK therapy can be prepared and administered without donor compatibility constraints.
- Combination-friendlyCIK cells synergise with chemotherapy, radiotherapy, RFA, and TACE โ making them highly compatible as an adjunct component of multimodal cancer treatment plans.
- Broad tumour applicabilityClinical evidence exists across liver, lung, gastric, colorectal, renal, and haematological cancers โ not limited to a single indication.
- Outpatient-friendly infusionCIK infusions are typically administered in an outpatient or day-ward setting, with minimal infusion-related adverse events.
Limitations
- Lower specificity than CAR-TCIK cells recognise tumours broadly rather than targeting a defined antigen โ response rates in haematological malignancies are generally lower than antigen-specific engineered T cells.
- Variable clinical trial qualityMany published CIK trials, particularly older Chinese studies, are small and lack robust randomisation โ making effect size estimation uncertain.
- Not yet globally standard-of-careOutside China and East Asia, CIK therapy is not included in major Western oncology guidelines (NCCN, ESMO) as first- or second-line treatment.
- Multiple infusion cycles requiredCIK therapy typically involves repeated infusion cycles over several weeks or months, requiring ongoing hospital attendance or coordination.
CIK Therapy โ Key Clinical Numbers
These figures reflect the breadth and maturity of the CIK clinical evidence base, concentrated primarily in Chinese academic cancer centres.
- 100+Randomised controlled trials published on CIK therapyThe largest evidence base of any adoptive cell therapy โ predominantly from Chinese centres across multiple solid tumour types.
- CD3+CD56+Defining surface marker of CIK cellsThis co-expression profile confers both T-cell and NK-cell cytotoxic properties on the infused population.
- 14โ21 daysTypical ex vivo expansion periodFrom blood draw to infusion-ready product โ making CIK one of the fastest adoptive cell therapies to manufacture.
Which Cancers Is CIK Therapy Used For?
CIK therapy has been studied and applied most extensively in solid tumours where liver involvement, post-surgical recurrence prevention, or combination with locoregional therapy is relevant.
Hepatocellular Carcinoma (HCC)
The strongest evidence base for CIK exists in liver cancer, where it is used post-resection, post-TACE, and post-RFA to reduce recurrence and improve disease-free survival.
Non-Small Cell Lung Cancer
Multiple RCTs show improved overall survival and progression-free survival when CIK is added to standard chemotherapy or following surgical resection for stage IIโIII NSCLC.
Gastric Cancer
CIK combined with chemotherapy has demonstrated improved survival outcomes in Chinese trials, particularly for patients with locally advanced or post-resection gastric cancer.
Colorectal, Renal & Other Solid Tumours
Growing evidence supports CIK use in colorectal, renal cell carcinoma, and nasopharyngeal carcinoma โ primarily in combination settings or as maintenance therapy.
More from the CIK Cell Therapy Resource Library
Continue exploring โ from the manufacturing process to disease-specific evidence and how CIK compares with CAR-T.
Frequently Asked Questions About CIK Therapy
The most common questions from patients and families considering CIK cell therapy for the first time.
Is CIK therapy the same as immunotherapy?
CIK therapy is a specific form of adoptive cellular immunotherapy โ a category of immunotherapy that involves extracting, expanding, and re-infusing immune cells. It is distinct from checkpoint inhibitor immunotherapy (such as pembrolizumab or nivolumab), which works by blocking inhibitory receptors on existing immune cells rather than expanding and re-infusing new ones. Both fall under the broader umbrella of cancer immunotherapy.
How is CIK therapy different from CAR-T cell therapy?
The fundamental difference is specificity. CAR-T cells are genetically engineered to express a chimeric antigen receptor that locks on to a single tumour antigen โ making them highly potent but narrowly targeted and potentially toxic. CIK cells are not genetically modified; they are expanded and activated using cytokines, and they kill tumours broadly through MHC-unrestricted mechanisms. CIK is safer and more broadly applicable; CAR-T achieves higher response rates in specific blood cancers. See our dedicated comparison page for a full breakdown.
Does CIK therapy work as a standalone treatment or only in combination?
CIK therapy has been studied both as monotherapy and in combination. The strongest evidence comes from combination use โ particularly with chemotherapy, post-surgical adjuvant therapy, post-TACE in liver cancer, and post-RFA ablation. As a standalone therapy, CIK shows more modest effects. Most oncologists at specialist centres use it as part of a multimodal strategy rather than as a sole treatment.
Where is CIK therapy available?
CIK therapy has the deepest clinical infrastructure in China, where it has been studied and applied for over two decades at major academic cancer centres. It is also available at selected centres in South Korea, Taiwan, Japan, and India. In Western countries, CIK remains primarily investigational and is not part of standard clinical protocols. CancerFax specialises in coordinating access to CIK therapy at vetted centres in China and India.
Is CIK therapy covered by insurance?
In China, CIK therapy is offered at leading cancer centres under research and clinical programmes โ insurance coverage varies by province and hospital arrangement. For international patients travelling to China for CIK therapy, treatment is generally self-funded. CancerFax can provide a detailed cost estimate for your specific treatment plan before you commit to travel.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Is CIK Therapy an Option for Your Case?
CancerFax reviews your medical records and identifies whether CIK therapy โ alone or in combination โ may be appropriate for your cancer type, stage, and treatment history, then connects you with specialist centres in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.